HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer's Disease.
NEW YORK, March 19, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), is pleased to unveil positive pre-clinical research showcasing the potential of HT-ALZ, an innovative Alzheimer's disease therapeutic. Targeting the Substance P/Neurokinin 1 Receptor pathway, HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer's Disease.
This pioneering study, conducted by a distinguished team of researchers including Carla Yuede, Kate M. Reardon, Ryan T. Harrigan, and John R. Cirrito, among others, highlights HT-ALZ's profound impact on Alzheimer's pathology. By specifically antagonizing the NK1 receptor, HT-ALZ not only reduces soluble Aß levels in the brain's interstitial fluid but also significantly diminishes anxiety-like behavior and enhances cognitive function in preclinical models.
The research presents compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheimer's disease treatment. While the effects on plaque deposition and Aß levels were inconclusive, the treatment's cognitive benefits suggest that HT-ALZ's mode of action may involve a reduction in brain inflammation, thereby improving cognitive outcomes for Alzheimer's patients.
HT-ALZ's pre-clinical significance lies in its ability to restore cognitive functions and improve quality of life for subjects suffering from Alzheimer's disease, offering a beacon of hope.
Hoth Therapeutics remains committed to further research and development of HT-ALZ, including detailed analyses of its effects on microglial activation and brain inflammation. The company is optimistic about HT-ALZ's path toward. The full manuscript of the study will be published later this year and we look forward to a presentation of the results by the scientists named above who will be sharing this data at an Alzheimer's Research Center group at Washington University in St Louis.
For more information on Hoth Therapeutics and our innovative approach to Alzheimer's disease treatment with HT-ALZ, please visit https://hoththerapeutics.com
About Hoth Therapeutics, Inc.
Recent HOTH News
- Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024 • PR Newswire (US) • 05/01/2024 12:00:00 PM
- Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds • PR Newswire (US) • 03/27/2024 06:00:00 PM
- Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment • PR Newswire (US) • 03/27/2024 12:27:00 PM
- Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ • PR Newswire (US) • 03/19/2024 12:21:00 PM
- Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio • PR Newswire (US) • 02/29/2024 01:38:00 PM
- Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic • PR Newswire (US) • 02/26/2024 01:11:00 PM
- Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024 • PR Newswire (US) • 02/13/2024 04:45:00 PM
- Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients • PR Newswire (US) • 01/18/2024 01:20:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 08:03:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 10:01:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 10:01:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 10:01:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 10:01:05 PM
- Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami • PR Newswire (US) • 12/27/2023 01:21:00 PM
- Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies • PR Newswire (US) • 12/05/2023 01:33:00 PM
- Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT • PR Newswire (US) • 11/14/2023 01:37:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:16:03 PM
- Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023 • PR Newswire (US) • 11/10/2023 01:00:00 PM
- Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery • PR Newswire (US) • 10/05/2023 02:03:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 12:15:11 PM
- FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients • PR Newswire (US) • 10/02/2023 12:33:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/15/2023 08:15:38 PM
- Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules • PR Newswire (US) • 09/15/2023 06:38:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/14/2023 09:24:30 PM
- Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules • PR Newswire (US) • 09/13/2023 05:43:00 PM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM